Navigation auf


UZH Innovation Hub

Deana Mohr

Multisystem Cell Therapy for Improvement of Urinary Continence (MUS.I.C) REACHING THE PEOPLE

Deana Mohr and Team
Photo: Steve Kappenthuler, Deana Mohr, Jenny Prange (left to right)

Stress Urinary Incontinence (SUI), defined as the unintentional loss of urine, affects over 200 million people worldwide, with a prevalence of 20-50% in women. The currently available treatment options entail various complications. In the lab of Prof. Daniel Eberli, Deana Mohr finalized the development of a technology in tissue engineering using autologous muscle cells. This technology offers functional restoration of the damaged urinary sphincter muscle, thereby, representing an ideal treatment option that could reverse the underlying pathologic condition. During the Fellowship, Deana Mohr and her team plan to perform the necessary steps to bring this therapy to the people in need. This includes demonstrating the commercial potential of the approach, protecting the innovations, perform market research and setup an investment schema for the near and far future. 

Affiliation: Prof. Daniel Eberli

Start date: 07/2019


  • Deana Mohr co-founded the UZH Spin-off MUVON Therapeutics AG in 2019
  • MUVON is being accelerated by Wyss Zurich in 2021

  • MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition

  • MUVON wins second place at IFAS Innovation Challenge 2021

  • MUVON finishes as Top 3 finalist for the ZKB Pionierpreis 2023

Weiterführende Informationen


Dr. Deana Mohr


Muvon Therapeutics announces first patient enrolled in phase II clinical study.

MUVON Therapeutics

Regain control with personalized muscle regeneration

video muvon

MUVON supported by Wyss Zurich

At the end of the Fellowship Project, Deana founded the Spinoff MUVON. MUVON is supported by the joint ETH Zurich and UZH Accelerator Wyss Zurich.


Treatment Cycle